Abstract
Summary
CRISPR (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found in the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that had previously infected the prokaryote. They are used to detect and destroy DNA from similar bacteriophages during subsequent infections. Hence these sequences play a key role in the antiviral (i.e. anti-phage) defense system of prokaryotes.
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within organisms. This editing process has a wide variety of applications including basic biological research, development of biotechnology products, and treatment of diseases.
Diagram of the CRISPR prokaryotic antiviral defense mechanism. The CRISPR-Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages and provides a form of acquired immunity. RNA harboring the spacer sequence helps Cas (CRISPR-associated) proteins recognize and cut foreign pathogenic DNA.
Other RNA-guided Cas proteins cut foreign RNA. CRISPR are found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaea.
The global market for CRISPR & Cas Genes was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for CRISPR & Cas Genes was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CRISPR & Cas Genes was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for CRISPR & Cas Genes was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of CRISPR & Cas Genes include CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd. and Horizon Discovery Group Plc, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CRISPR & Cas Genes, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CRISPR & Cas Genes by region & country, by Type, and by Application.
The CRISPR & Cas Genes market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CRISPR & Cas Genes.
Market Segmentation
By Company
CRISPR Therapeutics
AstraZeneca
Addgene
Caribou Biosciences, Inc.
Cellectis
Editas Medicine, Inc.
Egenesis
F. Hoffmann-La Roche Ltd.
Horizon Discovery Group Plc
Genscrip
Danaher Corporation
Intellia Therapeutics, Inc.
Lonza
Merck KGaA
New England BioLabs
Takara Bio, Inc.
Synthego
Mammoth Biosciences
Inscripta, Inc.
Cibus
Segment by Type:
Vector-based Cas
DNA-free Cas
Cell Line Engineering
Segment by Application
Biotechnology and Pharmaceutical Companies
Academics and Government Research Institutes
Contract Research Organizations (CROs)
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CRISPR & Cas Genes manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CRISPR & Cas Genes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CRISPR & Cas Genes in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within organisms. This editing process has a wide variety of applications including basic biological research, development of biotechnology products, and treatment of diseases.
Diagram of the CRISPR prokaryotic antiviral defense mechanism. The CRISPR-Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages and provides a form of acquired immunity. RNA harboring the spacer sequence helps Cas (CRISPR-associated) proteins recognize and cut foreign pathogenic DNA.
Other RNA-guided Cas proteins cut foreign RNA. CRISPR are found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaea.
The global market for CRISPR & Cas Genes was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for CRISPR & Cas Genes was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CRISPR & Cas Genes was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for CRISPR & Cas Genes was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of CRISPR & Cas Genes include CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd. and Horizon Discovery Group Plc, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CRISPR & Cas Genes, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CRISPR & Cas Genes by region & country, by Type, and by Application.
The CRISPR & Cas Genes market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CRISPR & Cas Genes.
Market Segmentation
By Company
CRISPR Therapeutics
AstraZeneca
Addgene
Caribou Biosciences, Inc.
Cellectis
Editas Medicine, Inc.
Egenesis
F. Hoffmann-La Roche Ltd.
Horizon Discovery Group Plc
Genscrip
Danaher Corporation
Intellia Therapeutics, Inc.
Lonza
Merck KGaA
New England BioLabs
Takara Bio, Inc.
Synthego
Mammoth Biosciences
Inscripta, Inc.
Cibus
Segment by Type:
Vector-based Cas
DNA-free Cas
Cell Line Engineering
Segment by Application
Biotechnology and Pharmaceutical Companies
Academics and Government Research Institutes
Contract Research Organizations (CROs)
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CRISPR & Cas Genes manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CRISPR & Cas Genes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CRISPR & Cas Genes in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 CRISPR & Cas Genes Product Introduction
1.2 Global CRISPR & Cas Genes Market Size Forecast
1.3 CRISPR & Cas Genes Market Trends & Drivers
1.3.1 CRISPR & Cas Genes Industry Trends
1.3.2 CRISPR & Cas Genes Market Drivers & Opportunity
1.3.3 CRISPR & Cas Genes Market Challenges
1.3.4 CRISPR & Cas Genes Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CRISPR & Cas Genes Players Revenue Ranking (2023)
2.2 Global CRISPR & Cas Genes Revenue by Company (2019-2024)
2.3 Key Companies CRISPR & Cas Genes Manufacturing Base Distribution and Headquarters
2.4 Key Companies CRISPR & Cas Genes Product Offered
2.5 Key Companies Time to Begin Mass Production of CRISPR & Cas Genes
2.6 CRISPR & Cas Genes Market Competitive Analysis
2.6.1 CRISPR & Cas Genes Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CRISPR & Cas Genes Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CRISPR & Cas Genes as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Vector-based Cas
3.1.2 DNA-free Cas
3.1.3 Cell Line Engineering
3.2 Global CRISPR & Cas Genes Sales Value by Type
3.2.1 Global CRISPR & Cas Genes Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CRISPR & Cas Genes Sales Value, by Type (2019-2030)
3.2.3 Global CRISPR & Cas Genes Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Biotechnology and Pharmaceutical Companies
4.1.2 Academics and Government Research Institutes
4.1.3 Contract Research Organizations (CROs)
4.2 Global CRISPR & Cas Genes Sales Value by Application
4.2.1 Global CRISPR & Cas Genes Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CRISPR & Cas Genes Sales Value, by Application (2019-2030)
4.2.3 Global CRISPR & Cas Genes Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CRISPR & Cas Genes Sales Value by Region
5.1.1 Global CRISPR & Cas Genes Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CRISPR & Cas Genes Sales Value by Region (2019-2024)
5.1.3 Global CRISPR & Cas Genes Sales Value by Region (2025-2030)
5.1.4 Global CRISPR & Cas Genes Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CRISPR & Cas Genes Sales Value, 2019-2030
5.2.2 North America CRISPR & Cas Genes Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CRISPR & Cas Genes Sales Value, 2019-2030
5.3.2 Europe CRISPR & Cas Genes Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CRISPR & Cas Genes Sales Value, 2019-2030
5.4.2 Asia Pacific CRISPR & Cas Genes Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CRISPR & Cas Genes Sales Value, 2019-2030
5.5.2 South America CRISPR & Cas Genes Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CRISPR & Cas Genes Sales Value, 2019-2030
5.6.2 Middle East & Africa CRISPR & Cas Genes Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CRISPR & Cas Genes Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CRISPR & Cas Genes Sales Value
6.3 United States
6.3.1 United States CRISPR & Cas Genes Sales Value, 2019-2030
6.3.2 United States CRISPR & Cas Genes Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CRISPR & Cas Genes Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CRISPR & Cas Genes Sales Value, 2019-2030
6.4.2 Europe CRISPR & Cas Genes Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CRISPR & Cas Genes Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CRISPR & Cas Genes Sales Value, 2019-2030
6.5.2 China CRISPR & Cas Genes Sales Value by Type (%), 2023 VS 2030
6.5.3 China CRISPR & Cas Genes Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CRISPR & Cas Genes Sales Value, 2019-2030
6.6.2 Japan CRISPR & Cas Genes Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CRISPR & Cas Genes Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CRISPR & Cas Genes Sales Value, 2019-2030
6.7.2 South Korea CRISPR & Cas Genes Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CRISPR & Cas Genes Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CRISPR & Cas Genes Sales Value, 2019-2030
6.8.2 Southeast Asia CRISPR & Cas Genes Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CRISPR & Cas Genes Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CRISPR & Cas Genes Sales Value, 2019-2030
6.9.2 India CRISPR & Cas Genes Sales Value by Type (%), 2023 VS 2030
6.9.3 India CRISPR & Cas Genes Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 CRISPR Therapeutics
7.1.1 CRISPR Therapeutics Profile
7.1.2 CRISPR Therapeutics Main Business
7.1.3 CRISPR Therapeutics CRISPR & Cas Genes Products, Services and Solutions
7.1.4 CRISPR Therapeutics CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.1.5 CRISPR Therapeutics Recent Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Profile
7.2.2 AstraZeneca Main Business
7.2.3 AstraZeneca CRISPR & Cas Genes Products, Services and Solutions
7.2.4 AstraZeneca CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.2.5 AstraZeneca Recent Developments
7.3 Addgene
7.3.1 Addgene Profile
7.3.2 Addgene Main Business
7.3.3 Addgene CRISPR & Cas Genes Products, Services and Solutions
7.3.4 Addgene CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.3.5 Caribou Biosciences, Inc. Recent Developments
7.4 Caribou Biosciences, Inc.
7.4.1 Caribou Biosciences, Inc. Profile
7.4.2 Caribou Biosciences, Inc. Main Business
7.4.3 Caribou Biosciences, Inc. CRISPR & Cas Genes Products, Services and Solutions
7.4.4 Caribou Biosciences, Inc. CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.4.5 Caribou Biosciences, Inc. Recent Developments
7.5 Cellectis
7.5.1 Cellectis Profile
7.5.2 Cellectis Main Business
7.5.3 Cellectis CRISPR & Cas Genes Products, Services and Solutions
7.5.4 Cellectis CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.5.5 Cellectis Recent Developments
7.6 Editas Medicine, Inc.
7.6.1 Editas Medicine, Inc. Profile
7.6.2 Editas Medicine, Inc. Main Business
7.6.3 Editas Medicine, Inc. CRISPR & Cas Genes Products, Services and Solutions
7.6.4 Editas Medicine, Inc. CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.6.5 Editas Medicine, Inc. Recent Developments
7.7 Egenesis
7.7.1 Egenesis Profile
7.7.2 Egenesis Main Business
7.7.3 Egenesis CRISPR & Cas Genes Products, Services and Solutions
7.7.4 Egenesis CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.7.5 Egenesis Recent Developments
7.8 F. Hoffmann-La Roche Ltd.
7.8.1 F. Hoffmann-La Roche Ltd. Profile
7.8.2 F. Hoffmann-La Roche Ltd. Main Business
7.8.3 F. Hoffmann-La Roche Ltd. CRISPR & Cas Genes Products, Services and Solutions
7.8.4 F. Hoffmann-La Roche Ltd. CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.8.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.9 Horizon Discovery Group Plc
7.9.1 Horizon Discovery Group Plc Profile
7.9.2 Horizon Discovery Group Plc Main Business
7.9.3 Horizon Discovery Group Plc CRISPR & Cas Genes Products, Services and Solutions
7.9.4 Horizon Discovery Group Plc CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.9.5 Horizon Discovery Group Plc Recent Developments
7.10 Genscrip
7.10.1 Genscrip Profile
7.10.2 Genscrip Main Business
7.10.3 Genscrip CRISPR & Cas Genes Products, Services and Solutions
7.10.4 Genscrip CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.10.5 Genscrip Recent Developments
7.11 Danaher Corporation
7.11.1 Danaher Corporation Profile
7.11.2 Danaher Corporation Main Business
7.11.3 Danaher Corporation CRISPR & Cas Genes Products, Services and Solutions
7.11.4 Danaher Corporation CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.11.5 Danaher Corporation Recent Developments
7.12 Intellia Therapeutics, Inc.
7.12.1 Intellia Therapeutics, Inc. Profile
7.12.2 Intellia Therapeutics, Inc. Main Business
7.12.3 Intellia Therapeutics, Inc. CRISPR & Cas Genes Products, Services and Solutions
7.12.4 Intellia Therapeutics, Inc. CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.12.5 Intellia Therapeutics, Inc. Recent Developments
7.13 Lonza
7.13.1 Lonza Profile
7.13.2 Lonza Main Business
7.13.3 Lonza CRISPR & Cas Genes Products, Services and Solutions
7.13.4 Lonza CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.13.5 Lonza Recent Developments
7.14 Merck KGaA
7.14.1 Merck KGaA Profile
7.14.2 Merck KGaA Main Business
7.14.3 Merck KGaA CRISPR & Cas Genes Products, Services and Solutions
7.14.4 Merck KGaA CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.14.5 Merck KGaA Recent Developments
7.15 New England BioLabs
7.15.1 New England BioLabs Profile
7.15.2 New England BioLabs Main Business
7.15.3 New England BioLabs CRISPR & Cas Genes Products, Services and Solutions
7.15.4 New England BioLabs CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.15.5 New England BioLabs Recent Developments
7.16 Takara Bio, Inc.
7.16.1 Takara Bio, Inc. Profile
7.16.2 Takara Bio, Inc. Main Business
7.16.3 Takara Bio, Inc. CRISPR & Cas Genes Products, Services and Solutions
7.16.4 Takara Bio, Inc. CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.16.5 Takara Bio, Inc. Recent Developments
7.17 Synthego
7.17.1 Synthego Profile
7.17.2 Synthego Main Business
7.17.3 Synthego CRISPR & Cas Genes Products, Services and Solutions
7.17.4 Synthego CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.17.5 Synthego Recent Developments
7.18 Mammoth Biosciences
7.18.1 Mammoth Biosciences Profile
7.18.2 Mammoth Biosciences Main Business
7.18.3 Mammoth Biosciences CRISPR & Cas Genes Products, Services and Solutions
7.18.4 Mammoth Biosciences CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.18.5 Mammoth Biosciences Recent Developments
7.19 Inscripta, Inc.
7.19.1 Inscripta, Inc. Profile
7.19.2 Inscripta, Inc. Main Business
7.19.3 Inscripta, Inc. CRISPR & Cas Genes Products, Services and Solutions
7.19.4 Inscripta, Inc. CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.19.5 Inscripta, Inc. Recent Developments
7.20 Cibus
7.20.1 Cibus Profile
7.20.2 Cibus Main Business
7.20.3 Cibus CRISPR & Cas Genes Products, Services and Solutions
7.20.4 Cibus CRISPR & Cas Genes Revenue (US$ Million) & (2019-2024)
7.20.5 Cibus Recent Developments
8 Industry Chain Analysis
8.1 CRISPR & Cas Genes Industrial Chain
8.2 CRISPR & Cas Genes Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CRISPR & Cas Genes Sales Model
8.5.2 Sales Channel
8.5.3 CRISPR & Cas Genes Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer